About
Petra Budde is a biomarker and immunology executive focused on precision medicine, autoimmunity, oncology, and proteomics. She has served as Chief Scientific Officer at Oncimmune Germany GmbH since 2023 after leading medical research at Protagen AG and later serving as Director of Medical Research following Oncimmune's acquisition of Protagen in 2019. Her published consortium work and scientific leadership indicate influence through research, partnerships, and biomarker development rather than investing.
Areas of interest
biotechprecision medicinebiomarkersproteomicsimmunologyautoimmune diseaseoncologyclinical drug development